Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study-Reference-Cited by-同舟云学术

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study

Published:2023-03 Issue: Volume:10 Page:100139
ISSN:2772-3682
Container-title:The Lancet Regional Health - Southeast Asia
language:en
Short-container-title:The Lancet Regional Health - Southeast Asia

Author:

Kulkarni Prasad S.,Kadam Abhijit,Godbole Sheela,Bhatt Varsha^ORCID,Raut Abhishek^ORCID,Kohli Sunil,Tripathi Santanu,Kulkarni Praveen,Ludam Rakhi,Prabhu Madhav,Bavdekar Ashish,Gogtay Nithya J.,Meshram Sushant,Kadhiravan Tamilarasu,Kar Sonali^ORCID,Narayana D.H. Ashwath,Samuel Clarence,Kulkarni Govind,Gaidhane Abhay^ORCID,Sathyapalan Dipu^ORCID,Raut Sidram,Hadda Vijay,Bhalla Hira Lal,Bhamare Chetanraj,Dharmadhikari Abhijeet,Plested Joyce S.,Cloney-Clarke Shane,Zhu Mingzhu,Pryor Melinda,Hamilton Stephanie,Thakar Madhuri,Shete Ashwini,Gautam Manish,Gupta Nivedita,Panda Samiran,Shaligram Umesh,Poonawalla Cyrus S.,Bhargava Balram,Gunale Bhagwat,Kapse Dhananjay,Kanitkar Shubhangi A.,Kakrani Arjun L.,Tripathy Srikanth P.,Tilak Abhijit V.,Dhamne Akshay A.,Mirza Shahzad Beg,Athavale Prachi V.,Bhowmik Mandakini,Ratnakar Parag J.,Gupta Subodh,Deotale Vijayshri,Jain Jyoti,Kalantri Ashwini,Jain Vineet,Goyal Nidhi,Arya Alok,Rongsen-Chandola Temsunaro,Dasgupta Shreyasi,Periera Pratibha,A Vanmathi,Kawade Anand,Gondhali Arunkumar,Kudyar Palvi,Singh Abhishek,Yadav Ravi,Alexander Alina,Gunasekaran Venugopalan,Dineshbabu Sekar,Samantaray P.C.,Ravish H.S.,Kamra Deepshikha,Gaidhane Shilpa,Zahiruddin Quazi Syed,Moni Merlin,Kumar Anil,Dravid Ameet,Mohan Anant,Suri Tejas,Patel Tejas K.,Kishore Surekha,Choche Rahul,Ghatage Deepak,Salvi Sugam

Publisher

Elsevier BV

Reference25 articles.

1. Singh I, Patra G. Aerosol transmission of SARS-CoV-2: the unresolved paradox;Priyanka;Travel Med Infect Dis,2020

2. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine;Keech;N Engl J Med,2020

3. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial;Formica;PLoS Med,2021

4. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine;Heath;N Engl J Med,2021

5. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico;Dunkle;N Engl J Med,2022

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SAFETY AND IMMUNOGENICITY OF A PHH-1V BOOSTER DOSE AFTER DIFFERENT PRIME VACCINATION SCHEMES AGAINST COVID-19: PHASE III CLINICAL TRIAL FINAL RESULTS UP TO ONE YEAR;2024-05-14

2. Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial;Vaccine;2024-04

3. A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2–Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation;Microorganisms;2024-02-29

4. Protein subunit vaccines: Promising frontiers against COVID-19;Journal of Controlled Release;2024-02

5. Adverse events following immunization of ChAdOx1 nCoV-19 vaccine among healthcare workers of a medicine-teaching institution of North India;Journal of Family Medicine and Primary Care;2024-01